Patients with multiple sclerosis treated with natalizumab may rarely develop progressive multifocal leukoencephalopathy (PML), a serious and often fatal disease caused by infection with JC virus. The ...

Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...

Oral Presentation: Long-term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from Six Years of ULTIMATE I and II Open-label Extension BRIUMVI is a novel monoclonal antibody ...

Patients with multiple sclerosis (MS) should be evaluated before, and regularly during, treatment with fingolimod (Gilenya, Novartis) to identify signs and symptoms possibly linked to progressive ...

Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared ...

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ...

Biogen Idec Inc. and Elan Corp. plc reported two new cases of PML — though not much else, to the chagrin of investors and analysts — linked to multiple sclerosis therapy Tysabri (natalizumab), ...

Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple ...